IvelinRadkov/iStock via Getty Images
Avidity Biosciences (NASDAQ:RNA) has announced new data from its clinical trials evaluating the experimental treatment del-zota for Duchenne muscular dystrophy.
After one year of continuous treatment, participants showed not only a halt in disease progression, but also measurable improvements compared to their
The $1 trillion club used to be fairly exclusive. Now, it's becoming a lot more crowded. As of the time...
The biggest IPO ever is just a few weeks away as reports say SpaceX has accelerated its timeline for coming...
Throughout both of his terms, President Donald Trump has stood firm on immigration control, perhaps even more so this time...
While Warren Buffett has endorsed a value style of investing for decades, the other thing he frequently advocates for is...
About a decade ago, Tom Colicchio started writing checks. Not large ones at first, and not on his own thesis—he...
Maybe it’s time to stop mincing words about the stunning leftward turn of the Democratic Party by using descriptions such...
The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.
(1)-1024x683.jpg "State Department Says Remigration, Not Replacement Migration")
